
    
      Placebo-controlled double-masked, multiple dose Phase 2 study in 40 patients with IOP ≥ 22
      and ≤30 mmHg, evaluating ocular and systemic safety and efficacy following administration of
      Phentolamine mesylate 1.0% QD at 8PM to 10PM in both eyes for 14 days.
    
  